Photo by nci from unsplash
Patients with familial hypercholesteremia (FH) require lipoprotein aphaeresis (LA), mipomersen or lomitapide to control their LDL-C. Proprotein convertase subtisilin kexin type 9 (PCSK9) inhibitors have reduced the use of these… Click to show full abstract
Patients with familial hypercholesteremia (FH) require lipoprotein aphaeresis (LA), mipomersen or lomitapide to control their LDL-C. Proprotein convertase subtisilin kexin type 9 (PCSK9) inhibitors have reduced the use of these treatment strategies but some FH patients still require additional LDL-C
Keywords:
statins ezetimibe;
pcsk9 inhibitors;
hypercholesteremia statins;
ezetimibe pcsk9;
familial hypercholesteremia
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!